With Merck’s COVID Antiviral Announcement, Can the Pharma Pipeline Build Treatment Momentum?

 

At the start of the month, pharmaceutical company Merck dropped big news: It has developed a COVID antiviral drug that would cut hospitalization and mortality risks by 50%. In the drug’s study, patients taking the placebo pill saw 14% hospitalization rate and eight deaths, while the trial group with Merck’s drug had only 7% hospitalized and zero deaths.

This appears to be just the tip of the iceberg; Kaiser Health News reports at least three COVID antiviral candidates, including Merck’s, going through late-stage clinical trials, meaning a variety of COVID drugs could be on patient’s prescriptions here soon. What’ll be some of the positive domino effects to come from approval of COVID antivirals, not only on the pharmaceutical production pipeline, but on the general population’s health? Ira Leiderman, managing director of the healthcare practice at Cassel Salpeter & Co., gave MarketScale his take on the coming treatments.

Follow us on social media for the latest updates in B2B!

Image

Latest

healthcare
From the C-Suite to the Classroom: A Healthcare Leader’s Bet on the Next Generation
May 25, 2026

Healthcare isn’t short on strategy right now—it’s short on people, access, and experienced leadership where it matters most. In Texas alone, more rural hospitals have closed than in any other state over the past decade, leaving entire communities with limited access to care. At the same time, many health systems are realizing they haven’t…

Read More
AI
The AI Health Score: Turning Hallucinations, Agents, and AI Risk Into Board-Ready Insight
May 24, 2026

As artificial intelligence moves deeper into enterprise operations, many organizations are discovering that the real challenge is not adoption, but control. Traditional software has always been predictable: the same input produces the same output, making it possible to audit systems at a fixed point in time. AI changes that equation. Jeff Carson, founder of…

Read More
TheAIAudit
Introducing TheAIAudit: A Platform Built to Measure, Monitor, and Govern Enterprise AI
May 22, 2026

Enterprise AI is advancing faster than most companies can govern it. Behind the scenes, AI systems are already influencing decisions tied to revenue, operations, compliance, customer outcomes, and risk — yet many organizations still lack a clear way to measure, explain, or oversee what those systems are doing. That is the gap TheAIAudit was…

Read More
Leadership
How the Future of Work Is Being Reshaped by AI, Human Creativity, and Customer-Centered Leadership
May 21, 2026

As artificial intelligence rapidly reshapes industries, many professionals are asking the same urgent question: what happens when AI starts replacing not just repetitive tasks, but the foundational entry-level roles that once launched careers? According to Goldman Sachs Research, AI could expose the equivalent of 300 million jobs globally to automation, while potentially automating tasks…

Read More